Nurix reports preliminary cash $609.6M; plans pivotal CLL trials for NX-5948 in 2025

Nurix Therapeutics, Inc.

Preliminary cash and investments $609.6M as of Nov 30, 2024; runway into H1 2027.
NX-5948 achieved 75.5% ORR in CLL patients; FDA Fast Track and EMA PRIME designations.
Plans to initiate pivotal studies for NX-5948 in CLL in 2025; expand into WM and inflammatory indications.
Gilead exercised option on IRAK4 degrader; Sanofi collaboration extended; STAT6 degrader candidate nomination expected H1 2025.
Strengthened leadership: promoted Dr. O'Connor as CMO and Dr. Phiasivongsa as CTO; added Anil Kapur to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.